Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965726 · ClinicalTrials.gov registry record · Phase 2
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
A Phase 2 study, sponsored by Kanecia Obie Zimmerman.
- Completed
- Registry status
- Phase 2
- Development phase
- 964
- Enrollment target
NCT05965726: Completed Phase 2 study, sponsored by Kanecia Obie Zimmerman.
NCT05965726 is a Phase 2 study that has completed, run by Kanecia Obie Zimmerman. The registered enrollment target is 964 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (625% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05965726, a Phase 2 study, has completed, sponsored by Kanecia Obie Zimmerman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 964 participants
- Enrollment target
Study Summary
This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, multi-center, double-blind, randomized, controlled trial evaluating nirmatrelvir/ritonavir (Paxlovid) in two dosing durations for the treatment of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). The study is evaluating potential mechanisms of action, efficacy, and safety of antivirals and other therapeutics in individuals with PASC, according to the platform protocol objectives. The hypothesis is that persistent viral infection and/or overactive/chronic immune response and inflammation are underlying contributors to PASC and that antiviral and other applicable therapies may result in viral clearance or decreased inflammation and improvement in PASC symptoms.
Primary Outcome
PROMIS Cognitive 8a is a questionnaire assessing self-reported cognitive impairments over the past 7 days using 8 items. It assesses the frequency that respondents experienced cognitive impairments on a scale ranging from 5 (never) to 1 (very often; several times a day). The total raw score is transformed into a T-score, with higher scores representing better cognitive function. The T-scores are interpreted in relation to a US reference population and are scaled to have mean = 50 and SD = 10 in
Interventions
- DRUG Ritonavir
- DRUG Paxlovid
- DRUG Nirmatrelvir-matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 964 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 2 |
What the finished NCT05965726 record still lists
NCT05965726 is an interventional study that assigns participants to a tested intervention. The registered 964 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (625% higher).
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT05965726 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05965726 about?
NCT05965726 is a clinical study titled "RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms". This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This sub-study is a prospective, mul...
What is the current status of trial NCT05965726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 964 participants. The study started on 2023-07-26. Estimated completion is 2025-03-13.
What interventions are being tested in trial NCT05965726?
The interventions under investigation include: Ritonavir (DRUG), Paxlovid (DRUG), Nirmatrelvir-matching placebo (DRUG).
Who is sponsoring clinical trial NCT05965726?
This trial is sponsored by Kanecia Obie Zimmerman, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05965726's enrollment target sits among peer trials
964 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI